RNA Interference Market - Forecast(2022 - 2027)

Report Code: HCR 62940 Report Format: PDF + Excel

RNA Interference Market Overview

The RNA Interference Market size is estimated to reach $45.2 billion by 2027. Furthermore, it is poised to grow at a CAGR of 14.7% over the forecast period of 2022-2027. mRNA molecules have been the most utilized biochemical tool that has helped in the regulation of the predominant gene expression. The compendium, RNAi, which involves small RNAs, especially less than 30 bases helps in regulating the expression of a particular gene in a vast array of eukaryotic organisms. Primarily, RNAi was used to manipulate the gene expression in the Caenorhabditis elegans. Researchers have been undergoing studies to understand its multiplicative applications, and to date, RNAi can be successfully used in functional genomics, therapeutic interventions, agriculture or crop modifications, and various others. Additionally, it has been found that double stranded RNA was/is more potent and effective in producing interference than the individual strands. In the field, clinical trials are being rapidly paced, moreover, FDA has been keen on seeing the development of the RNAi owing to its spectacular abilities to help in curing high-fatality rate diseases. Owing to the growth of healthcare infrastructure alongside the development of robust technologies to substantiate its use in different applications have been the key drivers for the RNA Interference Industry in the forecast period.

RNA Interference Market Report Coverage

The report: RNA Interference Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the RNA Interference Market.

By Type- dsRNA, siRNA, and miRNA.
By Application- Drug Discovery and Development, Therapeutics, Agricultural Crop Modifications, and Others.
By End-Users- Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academia and Research Centers, and Others.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

  • Geographically, North America’s RNAi market held a dominant market share in the year 2021. It is owing to the region’s advanced outlook for developing technologically advanced and robust medical infrastructure. Moreover, the region has huge numbers of pioneers in the field/ market in consideration. However, Asia-Pacific is expected to offer lucrative growth opportunities to the marketers owing to the deployment and inclusion of FDI from the foreign players to outsource research-based activities.
  • The growing use of RNAi in cancer diagnosis and molecular diagnosis is the identified key driver for the market. However, unknown changes at the molecular levels while being adopted in disease ramifications are the market hurdles.
  • A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the RNA Interference Market Report.

RNA Interference Market- Geography (%) for 2021.

For More Details on This Report - Request for Sample

RNA Interference Market Segmentation Analysis- By Application

The RNA interference market based on application can be further segmented into Drug Discovery and Development, Therapeutics, Agricultural Crop Modifications, and Others. Therapeutics held a dominant market share in the year 2021. It is owing to the recent innovations, which have made it a popular alternative in the treatment of various diseases. Within the therapeutics, oncology, ocular disorders, hepatitis B and C, and various other neurological disorders can be ramified. Cancer, as governed by the WHO, is the second leading cause of death globally, and around 9.8 million deaths happened due to the said disease. The development of siRNA technology and its tolerance to nucleons helps in the development of non-viral vectors, which overcomes and facilitates its use in the therapeutic segments. Moreover, therapeutic segment is estimated to be the fastest-growing, with a CAGR of 15.4% over the forecast period of 2022-2027. It is owing to the multitudes of products under clinical-stage trials, and hence, the pipeline of product launches in the forecast period will help drive the segment.

RNA Interference Market Segmentation Analysis- By End-Users

The RNA interference market based on end-users can be further segmented into Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academia and Research Centers, and Others. Pharmaceutical and Biotechnology companies held a dominant market share in the year 2021. It is owing to vast research being done by the following users. Moreover, predominant companies spent heavily in the period of 2022-2021. For example, Incyte spent $2.216 billion in 2020, which in the former year was $1.1 billion. Additionally, the predominant position was seen in number of employees being held in the R&D team. As for Incyte, 930worked in the R&D team out of 1773 employees.

However, Contract Research Organizations are estimated to be the fastest-growing, with a CAGR of 15.6% over the forecast period of 2022-2027. It is owing to the rising preferences of the foreign drug researchers to outsource the research pertaining activities to foreign locations, which in turn helps them in saving costs and the additional activities to hire pupils for different activities and purposes.

RNA Interference Market Segmentation Analysis- By Geography

The RNA Interference Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. Geographically, North America’s RNAi market held a dominant market share of 34% over the other regions in the year 2021. It is owing to the region’s advanced outlook for developing technologically advanced and robust medical infrastructure. Moreover, countries like the US spends around $11582 per person, and has been seeing an increment allocation for healthcare budgets. Lastly, major drug and pharma companies are headquartered in the said region, which further allowed the market to hold a significant share.

Moreover, Asia-Pacific is estimated to offer lucrative growth opportunities to marketers in the projected period of 2022-2027. It is owing to the rising focus of various countries to enhance their medical infrastructure, and fund projects which have the potential to reduce disease fatality. Furthermore, India saw a 137% increase in the budgetary allocation for its healthcare in 2021 from 2020. Such aspects will allow the region to grow.

RNA Interference Market Drivers

The use of RNAi in cancer therapy and molecular diagnosis has been the penultimate driving factor for the market

The effectiveness of using RNAis for cancer therapy has been a much-researched topic for a decade and a more. By induction of silencing in the advanced stages of growth-transmission of the silenced gene to the next generation-and low cost compared to the other potential methods of gene therapy, especially its high specificity compared to the other methods such as chemotherapy are its prime advantages. Owing to its precise functional mechanisms, and high specificity, it is successful in targeting multiple genes, which are of different cell pathways, thereby involved in tumor progression. Moreover, specific drugs can be developed which are personalized on the need of a patient, which has the potential to stop the tumor growth. Lastly, using the said methodology, it can overcome the potential bottleneck of drug resistance. Furthermore, the case load of cancer has been growing in some regions, while in some it has remained constant. For example, around 2 million cases of cancer came forward in the US for the year 2021.

The growing inclination to develop better medical infrastructural capabilities has aided in the market growth

Healthcare expenditure is a growing aspect for the government. Moreover, countries like the US spent close to $21 billion to treat cancer in the year 2021. Thereby, federal bodies are now looking to bring private players in the field of chemical biology, which carries the potential to eliminate the disease at its benign stage. The following strategies help both parties. For one, start-ups or researchers can fund their studies, and if successful the medication/ treatment line can help in saving billions of dollars for the federal government. Moreover, the recent projections are highly influenced by the growing geriatric population, hence, countries like the US are estimating the healthcare cost to increase by nearly 20% in the next decade. To overcome those costs, private players are heavily motivated to find solutions.

RNA Interference Market Challenges

The operational challenge(s) in directing the RNAi to the desired organs along with unknown challenges at the cell levels poses itself as a market challenge

The small double-stranded RNAi can efficiently target or trigger the transcriptional gene silencing. However, the delivery of siRNA poses a major challenge in the therapeutic approach for humans. The barriers are heavily dependent on the target organs and dependant on the route of administration. RNAi can be potentially delivered via systemic administration and localized administration. The former offers more challenges than the latter, as the latter offers high bio-availability of the target site and avoids barriers to the target site. The siRNA systemic delivery has various challenges that limit the siRNA bioavailability at the target site. Upon intravenous injection, unmodified naked siRNA is degraded by endogenous enzymes. Also, due to their small size siRNA is eliminated through kidneys. The siRNA is a negatively charged molecule, and it is almost impossible for siRNA to cross the biological membrane.

RNA Interference Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the RNA Interference Market. RNA Interference top 10 companies include:

  1. Alnylam Pharmaceuticals
  2. Arcturus Therapeutics
  3. Arrowhead
  4. Dicerna Pharmaceuticals
  5. Quark Pharmaceuticals Inc.
  6. Ionis Pharmaceuticals Inc.
  7. Merck & Co. Inc. (Sigma Aldrich)
  8. Silence Therapeutics PLC
  9. Qiagen NV
  10. Phio Pharmaceuticals Corp.

Recent Developments

  • In October 2021, Alnylam Pharmaceutical Inc announced its phase-3 study of Vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis. The following gained fast track approval from FDI, as it scored Neuropathy Impairment Score of mNIS+7, and all the other required markers were well tolerated. Moreover, the results also established that the reduction of neurologic impairment and improvement in life was observed and maintained.
  • In October 2021, Dicerna Pharmaceutical announced its results for the PHYOX4, which evaluated the study and tolerability of a single subcutaneous dose of Nedosiran. The therapy targets the hepatic enzyme lactate dehydrogenase, whereas lumasiran targets the hepatic enzyme glyoxylate oxidase. Dicerna has received Breakthrough Therapy and Rare Pediatric Disease designations from the FDA.
  • In October 2021, Teprasiran, from Quark Pharmaceuticals and licensed to Novartis, is being developed as a prophylactic treatment for acute kidney injury (AKI) after transplant or cardiovascular surgery. The therapy has undergone several clinical trials and Quark is currently recruiting for a phase 3 trial to test teprasiran against placebo in patients at high risk for AKI following cardiovascular surgery. 

Relevant Titles

Gene Expression Analysis Market-Forecast (2022-2027)

Report Code-HCR 0415

RNA Sequencing Market- Forecast (2022-2027)

Report Code- HCR 14761 

For more Lifesciences and Healthcare Market reports, please click here

1. RNA Interference Market Overview
    1.1 Definitions and Scope
2. RNA Interference Market- Executive Summary
3. RNA Interference Market – Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis 
4. RNA Interference Market – Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. RNA Interference Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. RNA Interference Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. RNA Interference Market – By Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. RNA Interference Market- By Type (Market Size –$Million/$Billion) 
    8.1 dsRNA
    8.2 siRNA
    8.3 miRNA
9. RNA Interference Market- By Application (Market Size –$Million/$Billion) 
    9.1 Drug Discovery and Development
    9.2 Therapeutics
        9.2.1 Oncology
        9.2.2 Ocular Disorders
        9.2.3 Hepatitis B and C
        9.2.4 Others
    9.3 Agricultural Crop Modifications
    9.4 Others
10. RNA Interference Market- By End-Users (Market Size –$Million/$Billion) 
    10.1 Pharmaceutical and Biotechnology
    10.2 Contract Research Organizations
    10.3 Academia and Research Centers
    10.4 Others
11. RNA Interference Market - By Geography (Market Size -$Million/Billion)
    11.1 North America
        11.1.1 U.S
        11.1.2 Canada
        11.1.3 Mexico
    11.2 South America
        11.2.1 Brazil
        11.2.2 Argentina
        11.2.3 Chile
        11.2.4 Colombia
        11.2.5 Rest of South America
    11.3 Europe
        11.3.1 Germany
        11.3.2 France
        11.3.3 UK
        11.3.4 Italy
        11.3.5 Spain
        11.3.6 Russia
        11.3.7 Rest of Europe
    11.4 Asia-Pacific
        11.4.1 China
        11.4.2 Japan
        11.4.3 South Korea
        11.4.4 India
        11.4.5 Australia & New Zealand
        11.4.6 Rest of APAC
    11.5 Rest of the World
        11.5.1 Middle East
        11.5.2 Africa
12. RNA Interference Market - Market Entropy
    12.1 New product launches
    12.2 M&A's, collaborations, JVs, and partnerships
13. RNA Interference Market – Industry Competition Landscape (Premium)
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key Companies
        13.1.3 Market Share by Countries – Key Companies
    13.2 Competition Matrix
    13.3 Best Practices for Companies
14. RNA Interference Market – Key Company List by Country Premium (Premium)
15. RNA Interference Market - Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies

LIST OF TABLES

1.Global Rnai Drug Delivery Market, By Drug Delivery Technology Market 2019-2024 ($M)
1.1 Nanoparticle Drug Delivery Technology Market 2019-2024 ($M) - Global Industry Research
1.2 Pulmonary Drug Delivery Technology Market 2019-2024 ($M) - Global Industry Research
1.3 Nucliec Acid Drug Delivery Technology Market 2019-2024 ($M) - Global Industry Research
1.4 Aptamer Drug Delivery Technology Market 2019-2024 ($M) - Global Industry Research
2.Global Rnai Drug Delivery Market, By Drug Delivery Technology Market 2019-2024 (Volume/Units)
2.1 Nanoparticle Drug Delivery Technology Market 2019-2024 (Volume/Units) - Global Industry Research
2.2 Pulmonary Drug Delivery Technology Market 2019-2024 (Volume/Units) - Global Industry Research
2.3 Nucliec Acid Drug Delivery Technology Market 2019-2024 (Volume/Units) - Global Industry Research
2.4 Aptamer Drug Delivery Technology Market 2019-2024 (Volume/Units) - Global Industry Research
3.North America Rnai Drug Delivery Market, By Drug Delivery Technology Market 2019-2024 ($M)
3.1 Nanoparticle Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
3.2 Pulmonary Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
3.3 Nucliec Acid Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
3.4 Aptamer Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
4.South America Rnai Drug Delivery Market, By Drug Delivery Technology Market 2019-2024 ($M)
4.1 Nanoparticle Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
4.2 Pulmonary Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
4.3 Nucliec Acid Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
4.4 Aptamer Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
5.Europe Rnai Drug Delivery Market, By Drug Delivery Technology Market 2019-2024 ($M)
5.1 Nanoparticle Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
5.2 Pulmonary Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
5.3 Nucliec Acid Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
5.4 Aptamer Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
6.APAC Rnai Drug Delivery Market, By Drug Delivery Technology Market 2019-2024 ($M)
6.1 Nanoparticle Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
6.2 Pulmonary Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
6.3 Nucliec Acid Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
6.4 Aptamer Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
7.MENA Rnai Drug Delivery Market, By Drug Delivery Technology Market 2019-2024 ($M)
7.1 Nanoparticle Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
7.2 Pulmonary Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
7.3 Nucliec Acid Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research
7.4 Aptamer Drug Delivery Technology Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US RNA Interference Market Revenue, 2019-2024 ($M)
2.Canada RNA Interference Market Revenue, 2019-2024 ($M)
3.Mexico RNA Interference Market Revenue, 2019-2024 ($M)
4.Brazil RNA Interference Market Revenue, 2019-2024 ($M)
5.Argentina RNA Interference Market Revenue, 2019-2024 ($M)
6.Peru RNA Interference Market Revenue, 2019-2024 ($M)
7.Colombia RNA Interference Market Revenue, 2019-2024 ($M)
8.Chile RNA Interference Market Revenue, 2019-2024 ($M)
9.Rest of South America RNA Interference Market Revenue, 2019-2024 ($M)
10.UK RNA Interference Market Revenue, 2019-2024 ($M)
11.Germany RNA Interference Market Revenue, 2019-2024 ($M)
12.France RNA Interference Market Revenue, 2019-2024 ($M)
13.Italy RNA Interference Market Revenue, 2019-2024 ($M)
14.Spain RNA Interference Market Revenue, 2019-2024 ($M)
15.Rest of Europe RNA Interference Market Revenue, 2019-2024 ($M)
16.China RNA Interference Market Revenue, 2019-2024 ($M)
17.India RNA Interference Market Revenue, 2019-2024 ($M)
18.Japan RNA Interference Market Revenue, 2019-2024 ($M)
19.South Korea RNA Interference Market Revenue, 2019-2024 ($M)
20.South Africa RNA Interference Market Revenue, 2019-2024 ($M)
21.North America RNA Interference By Application
22.South America RNA Interference By Application
23.Europe RNA Interference By Application
24.APAC RNA Interference By Application
25.MENA RNA Interference By Application
26.Tekmira Pharmaceutical Corp, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Alnylam Pharmaceutical Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Merck Co Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Isi Pharmaceuticals, Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Access Pharmaceutical Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Dicerna Pharmaceutical Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Calondo Pharmaceutical Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Marina Biotech Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Rxi Pharmaceutical Corp, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Quark Pharmaceutical Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)